Developing a new RNA-based vaccine for avian influenza
Rapid response to pandemic influenza via multi-antigen RNA-based vaccine
This study is testing a new type of vaccine for the H7N9 bird flu virus, which can cause serious illness, to see if it can create a strong immune response with fewer side effects, and it's aimed at helping people stay safe during outbreaks.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tiba Biotech, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10920420 on NIH RePORTER |
What this research studies
This research focuses on creating a rapid-response vaccine for the avian influenza A H7N9 virus, which poses a significant risk of severe respiratory illness and potential pandemics. The approach utilizes a novel RNA vaccine technology that aims to induce strong immune responses with less inflammation compared to traditional vaccines. By using a proprietary delivery system, the researchers hope to improve vaccine stability and effectiveness, making it easier to deploy during health crises. The study involves preclinical testing in mice to evaluate the immune response generated by the vaccine formulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for avian influenza exposure, such as poultry workers or those in close contact with birds.
Not a fit: Patients who are not at risk for avian influenza or those who have already been vaccinated against it may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and rapidly deployable vaccine for avian influenza, potentially saving lives during future outbreaks.
How similar studies have performed: Other research has shown promise in using RNA vaccine technology for rapid responses to viral outbreaks, particularly during the COVID-19 pandemic.
Where this research is happening
Cambridge, United States
- Tiba Biotech, LLC — Cambridge, United States (Active)
Researchers
- Principal investigator: Chahal, Jasdave — Tiba Biotech, LLC
- Study coordinator: Chahal, Jasdave
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.